INTERPACE BIOSCIENCES, INC. (symbol: IDXG) is the issuer of record for a Form 4 filing submitted to the SEC.
INTERPACE BIOSCIENCES, INC. (symbol: IDXG) is the issuer of record for a Form 4 filing submitted to the SEC.
INTERPACE BIOSCIENCES, INC. (IDXG) reported equity compensation transactions for CFO & COO Christopher McCarthy on August 20, 2026. He was granted 554,018 RSUs, of which 277,009 vested immediately and converted into common stock, with 277,009 RSUs scheduled to vest on August 20, 2027, subject to continued service. He also received a stock option for 277,009 shares of common stock at an exercise price of $2.02 per share, expiring August 20, 2036, vesting in four equal annual installments beginning August 20, 2027. After these transactions, he directly held 323,800 shares of common stock.
Interpace Biosciences reported Q2 2026 results showing improved profitability and margins as a thyroid-only diagnostics business. Revenue was $9.1 million, down 1% from $9.2 million reported a year earlier but up 9% from $8.4 million on a Pro Forma basis excluding the discontinued PancraGEN® business. Gross profit margin rose to 62% from 57% reported and 54% Pro Forma, and operating income was $0.3 million compared with operating losses in the prior-year quarter. Income from continuing operations was $0.3 million versus a $0.5 million loss a year ago.
Adjusted EBITDA increased to $0.7 million, or 8% of revenue, from $0.2 million on a Pro Forma basis, aided by higher thyroid revenue and efficiency gains, despite approximately $0.2 million of non-recurring professional fees. For the first six months of 2026, revenue was $18.2 million, up 12% from the prior-year Pro Forma period, with a 64% gross margin and $1.1 million of income from continuing operations. Adjusted EBITDA for the half-year was $2.3 million, or 13% of revenue.
The company highlighted a debt-free balance sheet, thyroid test volume growth, and operational metrics such as improved days sales outstanding and turnaround time. It also outlined a pancreatic cancer testing program in development and plans to add a Chief Scientific Officer in September 2026.
Interpace Biosciences, Inc. reported continued profitability for the quarter and six months ended June 30, 2026 while managing through the loss of reimbursement for its PancraGEN® pancreatic test. For the quarter, revenue was $9.1 million versus $9.2 million a year earlier, with income from continuing operations of $0.3 million compared with a loss of $0.5 million. For the six months, revenue was $18.2 million, down 12% from $20.7 million, but income from continuing operations remained solid at $1.1 million versus $1.2 million.
Cost controls improved profitability: gross margin from continuing operations rose to 63.6% for the first half of 2026, and sales and marketing expenses fell meaningfully after prior-year severance tied to PancraGEN®’s discontinuation. Adjusted EBITDA from continuing operations was $2.3 million for the first half. Cash from operations was $0.4 million and cash and cash equivalents were $2.7 million at June 30, 2026, with management stating these resources and forecasted receipts are expected to cover cash needs for the next twelve months.
Capital structure changed significantly: on January 20, 2026 all 47,000 shares of Series C Preferred Stock converted into 23,267,327 common shares, leaving 27,700,904 common shares outstanding at June 30, 2026. Two investors, Ampersand and 1315 Capital, together held about 84% of the common stock after conversion. The former Term Loan has been repaid, and the company is exploring strategic and financing alternatives and seeking an uplisting of its common stock to Nasdaq.
Interpace Biosciences is asking stockholders at its virtual August 20, 2026 annual meeting to approve several significant governance and capital structure changes. The company proposes an amended and restated charter that would double authorized common shares to 200,000,000, declassify the board so all directors stand for annual election, remove 75% supermajority voting requirements, expand director and officer liability protection, adopt exclusive forum clauses, and waive the corporate opportunity doctrine for directors and officers.
Stockholders are also being asked to grant the board discretionary authority to implement a reverse stock split between 1‑for‑2 and 1‑for‑10, mainly to support a potential Nasdaq uplisting from OTC trading. Additional items include approval of a new 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan, director elections structured differently depending on whether the new charter passes, an advisory say‑on‑pay vote, and ratification of EisnerAmper LLP as auditor. There were 27,700,904 common shares outstanding as of the June 29, 2026 record date, and two investors control about 84% of those shares.
Interpace Biosciences, Inc. is soliciting votes at its 2026 Annual Meeting to approve an Amended and Restated Certificate of Incorporation, authorize a reverse stock split (1-for-2 to 1-for-10), adopt a new 2026 Equity Incentive Plan, adopt a 2026 ESPP, elect directors and ratify EisnerAmper as auditor.
The proposal to increase authorized common shares would raise authorized common stock from 100,000,000 to 200,000,000. There were 27,700,904 shares outstanding as of the Record Date of June 29, 2026. The 2026 Plan would reserve a 4,400,000 share pool for new awards if approved.
Interpace Biosciences reported profitable first-quarter 2026 results while continuing its thyroid-only focus. Revenue was $9.0 million, down from $11.5 million a year earlier but up from $7.9 million on a Pro Forma basis that excludes the discontinued PancraGEN business. Gross margin improved to 65%, compared with 59% on a Pro Forma basis, reflecting better pricing and cost control in thyroid testing.
Income from continuing operations was $0.8 million versus $1.8 million a year ago, but higher than $0.4 million on a Pro Forma basis. Adjusted EBITDA reached $1.6 million, or 17% of revenue, up from $0.8 million and 10% on a Pro Forma basis. The company reaffirmed 2026 guidance for approximately 16% year-over-year thyroid revenue growth and highlighted higher average revenue per test, more accounts, and faster turnaround times. Interpace ended the quarter with $2.6 million in cash and no debt.
Interpace Biosciences reported lower revenue but remained profitable in the first quarter of 2026. Net revenue fell to $9.0 million from $11.5 million a year earlier, mainly because Medicare stopped reimbursing the discontinued PancraGEN test. Gross margin held at about 65%.
Net income decreased to $0.7 million from $1.6 million, while Adjusted EBITDA was $1.6 million versus $2.1 million. As of March 31, 2026, the company had $2.6 million in cash and $10.0 million in current assets against $4.0 million in current liabilities, and management believes available cash and forecast receipts will fund operations for at least 12 months.
In January 2026, all 47,000 shares of Series C Preferred Stock converted into about 23.3 million common shares, leaving 27,700,904 common shares outstanding. Two private equity investors now hold roughly 84% of the common stock. Interpace remains focused on its thyroid cancer tests ThyGeNEXT and ThyraMIR v2 and continues to evaluate financing and strategic alternatives, including a possible Nasdaq uplisting.